BIO-RAD LABORATORIES-A (BIO) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock
332.21 USD
+9.73 (+3.02%)
332.21 USD
0 (0%)
Overall BIO gets a fundamental rating of 4 out of 10. We evaluated BIO against 58 industry peers in the Life Sciences Tools & Services industry. BIO is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. BIO is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
In the past year BIO was profitable.
In the past year BIO had a positive cash flow from operations.
In multiple years BIO reported negative net income over the last 5 years.
BIO had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of BIO (-6.97%) is comparable to the rest of the industry.
Looking at the Return On Equity, with a value of -10.03%, BIO is in line with its industry, outperforming 51.72% of the companies in the same industry.
The Return On Invested Capital of BIO (2.26%) is better than 60.34% of its industry peers.
The Average Return On Invested Capital over the past 3 years for BIO is significantly below the industry average of 13.53%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROIC | 2.26% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
1.3 Margins
The Operating Margin of BIO (10.27%) is better than 68.97% of its industry peers.
In the last couple of years the Operating Margin of BIO has remained more or less at the same level.
With a decent Gross Margin value of 52.42%, BIO is doing good in the industry, outperforming 60.34% of the companies in the same industry.
In the last couple of years the Gross Margin of BIO has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% |
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), BIO is destroying value.
The number of shares outstanding for BIO has been reduced compared to 1 year ago.
Compared to 5 years ago, BIO has less shares outstanding
BIO has a worse debt/assets ratio than last year.
2.2 Solvency
BIO has an Altman-Z score of 3.49. This indicates that BIO is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 3.49, BIO is in the better half of the industry, outperforming 67.24% of the companies in the same industry.
BIO has a debt to FCF ratio of 3.57. This is a good value and a sign of high solvency as BIO would need 3.57 years to pay back of all of its debts.
BIO's Debt to FCF ratio of 3.57 is fine compared to the rest of the industry. BIO outperforms 75.86% of its industry peers.
BIO has a Debt/Equity ratio of 0.18. This is a healthy value indicating a solid balance between debt and equity.
BIO's Debt to Equity ratio of 0.18 is in line compared to the rest of the industry. BIO outperforms 56.90% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Altman-Z | 3.49 |
ROIC/WACC0.23
WACC9.8%
2.3 Liquidity
BIO has a Current Ratio of 5.44. This indicates that BIO is financially healthy and has no problem in meeting its short term obligations.
With an excellent Current ratio value of 5.44, BIO belongs to the best of the industry, outperforming 82.76% of the companies in the same industry.
A Quick Ratio of 3.94 indicates that BIO has no problem at all paying its short term obligations.
The Quick ratio of BIO (3.94) is better than 67.24% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 |
3. Growth
3.1 Past
BIO shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -1.90%.
The Earnings Per Share has been growing slightly by 7.84% on average over the past years.
Looking at the last year, BIO shows a decrease in Revenue. The Revenue has decreased by -0.88% in the last year.
The Revenue has been growing slightly by 2.11% on average over the past years.
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
3.2 Future
Based on estimates for the next years, BIO will show a decrease in Earnings Per Share. The EPS will decrease by -2.66% on average per year.
BIO is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 1.26% yearly.
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.66%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.26%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
BIO is valuated quite expensively with a Price/Earnings ratio of 32.22.
68.97% of the companies in the same industry are more expensive than BIO, based on the Price/Earnings ratio.
When comparing the Price/Earnings ratio of BIO to the average of the S&P500 Index (25.98), we can say BIO is valued slightly more expensively.
A Price/Forward Earnings ratio of 31.83 indicates a quite expensive valuation of BIO.
BIO's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. BIO is cheaper than 67.24% of the companies in the same industry.
BIO is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 35.79, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.22 | ||
| Fwd PE | 31.83 |
4.2 Price Multiples
77.59% of the companies in the same industry are more expensive than BIO, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.7 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)4.11
EPS Next 2Y0.61%
EPS Next 3Y4.05%
5. Dividend
5.1 Amount
No dividends for BIO!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
332.21
+9.73 (+3.02%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners89.73%
Inst Owner Change1.79%
Ins Owners3.84%
Ins Owner Change0%
Market Cap8.99B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Analysts76
Price Target362.1 (9%)
Short Float %5.06%
Short Ratio4.14
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)32.41%
Min EPS beat(2)15.74%
Max EPS beat(2)49.07%
EPS beat(4)4
Avg EPS beat(4)25.97%
Min EPS beat(4)0.1%
Max EPS beat(4)49.07%
EPS beat(8)8
Avg EPS beat(8)30.43%
EPS beat(12)9
Avg EPS beat(12)18.8%
EPS beat(16)12
Avg EPS beat(16)18.31%
Revenue beat(2)1
Avg Revenue beat(2)2.07%
Min Revenue beat(2)-0.73%
Max Revenue beat(2)4.87%
Revenue beat(4)2
Avg Revenue beat(4)0.63%
Min Revenue beat(4)-2.71%
Max Revenue beat(4)4.87%
Revenue beat(8)3
Avg Revenue beat(8)-0.13%
Revenue beat(12)3
Avg Revenue beat(12)-1.59%
Revenue beat(16)5
Avg Revenue beat(16)-1.12%
PT rev (1m)14.15%
PT rev (3m)9.01%
EPS NQ rev (1m)1.17%
EPS NQ rev (3m)-0.1%
EPS NY rev (1m)5.08%
EPS NY rev (3m)4.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-0.11%
Revenue NY rev (1m)-0.15%
Revenue NY rev (3m)-0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 32.22 | ||
| Fwd PE | 31.83 | ||
| P/S | 3.52 | ||
| P/FCF | 26.7 | ||
| P/OCF | 18.29 | ||
| P/B | 1.33 | ||
| P/tB | 1.56 | ||
| EV/EBITDA | N/A |
EPS(TTM)10.31
EY3.1%
EPS(NY)10.44
Fwd EY3.14%
FCF(TTM)12.44
FCFY3.75%
OCF(TTM)18.16
OCFY5.47%
SpS94.51
BVpS248.96
TBVpS213.22
PEG (NY)N/A
PEG (5Y)4.11
Graham Number240.32
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -6.97% | ||
| ROE | -10.03% | ||
| ROCE | 2.86% | ||
| ROIC | 2.26% | ||
| ROICexc | 2.67% | ||
| ROICexgc | 3.06% | ||
| OM | 10.27% | ||
| PM (TTM) | N/A | ||
| GM | 52.42% | ||
| FCFM | 13.17% |
ROA(3y)-17.25%
ROA(5y)0.31%
ROE(3y)-24.36%
ROE(5y)-0.68%
ROIC(3y)2.69%
ROIC(5y)2.68%
ROICexc(3y)3.18%
ROICexc(5y)3.05%
ROICexgc(3y)3.46%
ROICexgc(5y)3.26%
ROCE(3y)3.41%
ROCE(5y)3.39%
ROICexgc growth 3Y8.21%
ROICexgc growth 5Y0.05%
ROICexc growth 3Y5.9%
ROICexc growth 5Y-0.58%
OM growth 3Y-15.57%
OM growth 5Y1.1%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.9%
GM growth 5Y-0.31%
F-Score5
Asset Turnover0.26
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.18 | ||
| Debt/FCF | 3.57 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | 6.05% | ||
| Interest Coverage | -5.71 | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 5.44 | ||
| Quick Ratio | 3.94 | ||
| Altman-Z | 3.49 |
F-Score5
WACC9.8%
ROIC/WACC0.23
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)5.75%
Cap/Sales(5y)5.22%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-1.9%
EPS 3Y-13.02%
EPS 5Y7.84%
EPS Q2Q%12.44%
EPS Next Y-1.6%
EPS Next 2Y0.61%
EPS Next 3Y4.05%
EPS Next 5Y-2.66%
Revenue 1Y (TTM)-0.88%
Revenue growth 3Y-4.24%
Revenue growth 5Y2.11%
Sales Q2Q%0.5%
Revenue Next Year0.42%
Revenue Next 2Y1.43%
Revenue Next 3Y2.17%
Revenue Next 5Y1.26%
EBIT growth 1Y-23.49%
EBIT growth 3Y-19.14%
EBIT growth 5Y3.24%
EBIT Next Year33.54%
EBIT Next 3Y15.21%
EBIT Next 5Y6.94%
FCF growth 1Y50.11%
FCF growth 3Y-20.8%
FCF growth 5Y-5.83%
OCF growth 1Y31.59%
OCF growth 3Y-12.07%
OCF growth 5Y-0.12%
BIO-RAD LABORATORIES-A / BIO FAQ
What is the fundamental rating for BIO stock?
ChartMill assigns a fundamental rating of 4 / 10 to BIO.
What is the valuation status of BIO-RAD LABORATORIES-A (BIO) stock?
ChartMill assigns a valuation rating of 2 / 10 to BIO-RAD LABORATORIES-A (BIO). This can be considered as Overvalued.
What is the profitability of BIO stock?
BIO-RAD LABORATORIES-A (BIO) has a profitability rating of 4 / 10.
What are the PE and PB ratios of BIO-RAD LABORATORIES-A (BIO) stock?
The Price/Earnings (PE) ratio for BIO-RAD LABORATORIES-A (BIO) is 32.22 and the Price/Book (PB) ratio is 1.33.
What is the expected EPS growth for BIO-RAD LABORATORIES-A (BIO) stock?
The Earnings per Share (EPS) of BIO-RAD LABORATORIES-A (BIO) is expected to decline by -1.6% in the next year.